VSTM
HEALTHCAREVerastem Inc
$6.01+0.05 (+0.84%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VSTM Today?
No stock-specific AI insight has been generated for VSTM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.01$11.25
$6.01
Fundamentals
Market Cap$528M
P/E Ratio—
EPS$-3.02
Dividend Yield—
Dividend / Share—
ROE-14.8%
Profit Margin—
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding87.8M
VSTM News
20 articles- Verastem (VSTM) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian CancerYahoo Finance·May 8, 2026
- Verastem (VSTM) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business UpdatesBusiness Wire·May 7, 2026
- Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian CancerYahoo Finance·Apr 30, 2026
- Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 23, 2026
- Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s CancersYahoo Finance·Apr 10, 2026
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 2, 2026
- Cancer Stocks to Buy as Innovation Reshapes Global Oncology MarketYahoo Finance·Mar 26, 2026
- Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026Yahoo Finance·Mar 17, 2026
- Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s CancersYahoo Finance·Mar 17, 2026
- Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?Yahoo Finance·Mar 11, 2026
- Verastem (VSTM) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 5, 2026
- Verastem, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 5, 2026
- Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ...Yahoo Finance·Mar 5, 2026
- Verastem Q4 Earnings Call HighlightsMarketbeat·Mar 5, 2026
- Verastem (VSTM) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Mar 4, 2026
- Verastem: Q4 Earnings SnapshotYahoo Finance·Mar 4, 2026
- Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business UpdatesYahoo Finance·Mar 4, 2026
- Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026Yahoo Finance·Feb 18, 2026
All 20 articles loaded
Price Data
Open$5.93
Previous Close$5.96
Day High$6.10
Day Low$5.90
52 Week High$11.25
52 Week Low$4.01
52-Week Range
$4.01$11.25
$6.01
Fundamentals
Market Cap$528M
P/E Ratio—
EPS$-3.02
Dividend Yield—
Dividend / Share—
ROE-14.8%
Profit Margin—
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding87.8M
About Verastem Inc
Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in Needham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—